Kyle Rose

Stock Analyst at Canaccord Genuity

(2.66)
# 1,965
Out of 5,097 analysts
115
Total ratings
53.76%
Success rate
13.43%
Average return

Stocks Rated by Kyle Rose

Insulet
Dec 17, 2025
Maintains: Buy
Price Target: $432$450
Current: $291.57
Upside: +54.34%
Smith & Nephew
Feb 26, 2025
Maintains: Hold
Price Target: $27
Current: $33.12
Upside: -18.48%
Stryker
Jan 29, 2025
Maintains: Buy
Price Target: $420$435
Current: $356.52
Upside: +22.01%
Globus Medical
Dec 20, 2023
Maintains: Buy
Price Target: $67$71
Current: $89.36
Upside: -20.55%
Enovis
Dec 20, 2023
Maintains: Buy
Price Target: $65$71
Current: $27.20
Upside: +161.03%
InMode
Oct 13, 2023
Downgrades: Hold
Price Target: $55$22
Current: $14.43
Upside: +52.46%
The Beauty Health Company
Aug 25, 2023
Assumes: Buy
Price Target: $10
Current: $1.51
Upside: +562.25%
Alphatec Holdings
Aug 4, 2023
Maintains: Buy
Price Target: $17$22
Current: $20.70
Upside: +6.28%
DexCom
Jul 28, 2023
Maintains: Buy
Price Target: $135$150
Current: $67.43
Upside: +122.45%
Vicarious Surgical
May 31, 2023
Maintains: Buy
Price Target: $360$270
Current: $2.18
Upside: +12,285.32%
Maintains: Buy
Price Target: $24$27
Current: $20.81
Upside: +29.75%
Reiterates: Buy
Price Target: $15
Current: $1.14
Upside: +1,215.79%
Reiterates: Buy
Price Target: $15
Current: $32.74
Upside: -54.18%
Maintains: Market Perform
Price Target: $125$122
Current: $161.45
Upside: -24.43%
Upgrades: Buy
Price Target: $3$4
Current: $6.07
Upside: -34.10%
Downgrades: Hold
Price Target: n/a
Current: $7.48
Upside: -
Downgrades: Hold
Price Target: $165$125
Current: $89.80
Upside: +39.20%